Dr. Reddy’s Strengthens OTC Portfolio – Launches Nise D Spray

HYDERABAD, India–(BUSINESS WIRE)–Dr. Reddy’s today announced the launch of Nise D Spray, emphasizing its
strategic intent of being a player of substance in the Indian OTC (Over
The Counter) space. Nise D Spray offers quick and targeted pain killing.
Through this product Dr. Reddy’s has further expanded its offerings in
the therapeutic area of pain relief to consumers.

In India, the market for pain relief products is approximately INR 1,700
crore*. Pain relief sprays are growing 20 times faster than creams and
gels, indicating a trend of changing consumer preferences.

The formulation for Nise D Spray comprises 3 key ingredients which get
absorbed quicker, penetrate deep to reach the source of pain and reduce
inflammation.

Nise, as a brand, has been providing effective relief to consumers by
killing pain over the years. Nise believes in reaching out to consumers
at the point of incidence or in a relevant context. Nise was the
first-ever pain relief partner of the Indian Super League and various
marathons in key cities across India.

M V Ramana, EVP & Head Branded Markets (India & Emerging countries) –
Dr. Reddy’s, said, “Nise D Spray marks our entry into the new segment
and further boosts our OTC portfolio. Nise gel has made remarkable
headway into the market and looking at the market dynamics and consumer
requirements, we expect Nise D Spray to have a great momentum and
significant market share across regions.”

Nise D Spray will be available across all leading and neighborhood
pharmacy stores. It will be available in two convenient pack sizes –
pocket pack at INR 99/- and home pack for INR 130/-.

* A C Nielsen Retail Measurement Study MAT August 2015

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. is an integrated
pharmaceutical company, committed to accelerating access to affordable
and innovative medicines, because it believes Good Health Can’t Wait.
Through its three businesses – Pharmaceutical Services & Active
Ingredients, Global Generics and Proprietary Products – the company
offers a portfolio of products and services that include active
pharmaceutical ingredients (APIs), custom pharmaceutical services,
generics, biosimilars and differentiated formulations. With operations
in 26 countries across the globe, the major therapeutic areas of Dr.
Reddy’s are gastro-intestinal, cardiovascular, diabetology, oncology,
pain management and anti-infectives. For more information, log on to: www.drreddys.com.

Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on the
management’s current views and assumptions and involve known or unknown
risks and uncertainties that could cause actual results, performance or
events to differ materially from those expressed or implied in such
statements. In addition to statements which are forward-looking by
reason of context, the words “may,” “will,” “should,” “expects,”
“plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,”
“potential,” or “continue” and similar expressions identify
forward-looking statements. Actual results, performance or events may
differ materially from those in such statements due to without
limitation, (i) general economic conditions such as performance of
financial markets, credit defaults, currency exchange rates, interest
rates, persistency levels and frequency/severity of insured loss events,
(ii) mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws and
regulations and in the policies of central banks and/or governments, (v)
the impact of acquisitions or reorganisation, including related
integration issues.

The company assumes no obligation to update any information contained
herein.

Contacts

Dr. Reddy’s Laboratories Ltd.
INVESTOR RELATIONS
Kedar
Upadhye, +91-40-66834297
kedaru@drreddys.com
or
MEDIA
RELATIONS

Calvin Printer, +91-40-49002121
calvinprinter@drreddys.com